Published in Br J Clin Pharmacol on November 01, 2014
Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. J Vet Pharmacol Ther (2017) 0.75
A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics (1976) 13.83
Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Programs Biomed (2004) 5.13
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J (2011) 4.60
Diagnosing model diagnostics. Clin Pharmacol Ther (2007) 4.17
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn (2007) 3.00
Curvature in metabolic scaling. Nature (2010) 2.50
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant (2004) 1.77
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant (2007) 1.76
Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol (2010) 1.33
Tips and traps analyzing pediatric PK data. Paediatr Anaesth (2011) 1.22
Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit (2009) 1.11
Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem (1995) 1.11
A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet (2004) 1.08
Estimation of lean body mass in children. Br J Anaesth (2011) 1.08
Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet (2004) 1.05
Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit (2005) 1.04
Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci (2009) 0.99
Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res (2010) 0.98
The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet (2011) 0.97
Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol (2010) 0.96
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol (2013) 0.93
Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. Transplantation (2010) 0.93
Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. Clin Pharmacokinet (2009) 0.90
Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model). J Pharmacokinet Pharmacodyn (2012) 0.88
Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm (1992) 0.88
Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol (2013) 0.87
Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev (Orlando) (2011) 0.87
Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol (2010) 0.87
Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit (2007) 0.86
Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol (2010) 0.84
UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther (2009) 0.83
Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol (2012) 0.82
Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet? Clin Pharmacokinet (2011) 0.82
Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol (2010) 0.80
Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. J Clin Pharmacol (2011) 0.80
Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. Pharmacol Res (2011) 0.79
Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring. Scand J Clin Lab Invest (2013) 0.79
Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. Ther Drug Monit (2010) 0.78
Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. Ther Drug Monit (2010) 0.78
Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. Eur J Clin Pharmacol (2012) 0.78
Optimization of mycophenolic acid therapy using clinical pharmacometrics. Drug Metab Pharmacokinet (2013) 0.78
How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl Immunol (2002) 0.78
Effects of unbound mycophenolic acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients. Ther Drug Monit (2014) 0.77
The influence of context on quality improvement success in health care: a systematic review of the literature. Milbank Q (2010) 2.59
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet (2005) 2.09
System for integrated adherence monitoring: real-time non-adherence risk assessment in pediatric kidney transplantation. Pediatr Transplant (2012) 1.74
BK viremia precedes hemorrhagic cystitis in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2013) 1.62
Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood (2011) 1.43
Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children. Am J Kidney Dis (2012) 1.40
The impact of sirolimus on sex hormones in male adolescent kidney recipients. Pediatr Transplant (2012) 1.40
Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood (2013) 1.22
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.14
Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr (2011) 1.13
Lower vancomycin serum trough concentrations might not be the answer. Pediatr Infect Dis J (2013) 1.10
Continuous infusion of beta-lactams. Curr Opin Crit Care (2007) 1.08
The Allocation of Treatment Responsibility scale: a novel tool for assessing patient and caregiver management of pediatric medical treatment regimens. Pediatr Transplant (2010) 1.08
Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics (2002) 1.07
Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.04
Spontaneous closure of ventricular septal defects followed up from <3 months of age. Pediatr Int (2004) 1.02
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics (2006) 1.02
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology (2006) 1.01
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. Antimicrob Agents Chemother (2007) 1.01
Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer (2014) 1.01
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) (2010) 1.00
Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission. J Am Acad Child Adolesc Psychiatry (2003) 1.00
Dyslipidemia in children with chronic kidney disease. Kidney Int (2010) 0.99
Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet (2005) 0.98
Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum (2010) 0.98
Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant (2008) 0.98
Spontaneous closure of perimembranous ventricular septal defect after school age. Pediatr Int (2008) 0.97
The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet (2011) 0.97
Urocortin 3/stresscopin in human colon: possible modulators of gastrointestinal function during stressful conditions. Peptides (2005) 0.96
Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet (2009) 0.96
Gaining the PROMIS perspective from children with nephrotic syndrome: a Midwest pediatric nephrology consortium study. Health Qual Life Outcomes (2013) 0.96
Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol (2010) 0.96
Gaining the Patient Reported Outcomes Measurement Information System (PROMIS) perspective in chronic kidney disease: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol (2014) 0.94
Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion (2012) 0.94
Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation (2013) 0.94
Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights (2009) 0.93
Lipid rafts in cytokine signaling. Cytokine Growth Factor Rev (2004) 0.93
Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. Prostate (2006) 0.92
Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer (2003) 0.92
Identification of the novel splicing variants for the hPXR in human livers. Biochem Biophys Res Commun (2002) 0.91
Ephrin-B3-EphA4 interactions regulate the growth of specific thalamocortical axon populations in vitro. Eur J Neurosci (2002) 0.90
Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet (2007) 0.90
UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther Drug Monit (2012) 0.90
Propofol clearance in morbidly obese children and adolescents: influence of age and body size. Clin Pharmacokinet (2012) 0.88
Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant (2010) 0.88
Cystatin C-estimated glomerular filtration rate in pediatric autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 0.87
Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol (2005) 0.87
The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Ther Drug Monit (2014) 0.87
OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics (2013) 0.87
Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig (2013) 0.87
Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev (Orlando) (2011) 0.87
Pierson syndrome: a novel cause of congenital nephrotic syndrome. Pediatrics (2006) 0.86
Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Ther Drug Monit (2012) 0.86
Calpain II colocalizes with detergent-insoluble rafts on human and Jurkat T-cells. Biochem Biophys Res Commun (2002) 0.86
Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit (2007) 0.86
Identification of the genes that are expressed in the upper layers of the neocortex. Cereb Cortex (2004) 0.86
Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res (2004) 0.86
Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med (2013) 0.86
Optimal study design for pioglitazone in septic pediatric patients. J Pharmacokinet Pharmacodyn (2011) 0.86
Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther (2007) 0.85
Morphine clearance in children: does race or genetics matter? J Opioid Manag (2012) 0.85
Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2009) 0.84
Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. Ther Drug Monit (2013) 0.83
The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. J Clin Psychopharmacol (2008) 0.83
Psychosocial Assessment Tool 2.0_General: validity of a psychosocial risk screener in a pediatric kidney transplant sample. Pediatr Transplant (2011) 0.83
Federal legislation and the advancement of neonatal drug studies. J Pediatr (2012) 0.83
Pharmacogenetics in perioperative medicine. Curr Opin Anaesthesiol (2012) 0.83
Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol (2012) 0.82
Validation of a pediatric population pharmacokinetic model for vancomycin. Ther Drug Monit (2015) 0.82
Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Eur J Clin Pharmacol (2003) 0.82
Absorption and clearance of +/-3,4-methylenedioxymethamphetamine from the plasma of neonatal rats. Neurotoxicol Teratol (2004) 0.82
Update in fetal anesthesia for the ex utero intrapartum treatment (EXIT) procedure. Int Anesthesiol Clin (2012) 0.82
Pharmacodynamics of midazolam in pediatric intensive care patients. Ther Drug Monit (2005) 0.82
Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children. Br J Clin Pharmacol (2014) 0.82
Tacrolimus-based immunosuppression with steroid withdrawal in pediatric kidney transplantation--4-year experience at a moderate-volume center. Pediatr Transplant (2003) 0.82
Increasing incidence of post-kidney transplant anemia in children. Am J Transplant (2005) 0.82
Reliable individualized monitoring improves cholesterol control in kidney transplant recipients. Pediatrics (2013) 0.81
Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations. Clin Pharmacokinet (2005) 0.81
Better medicines for 300 million children in China: report on recent progress. Paediatr Drugs (2011) 0.81
Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. Transplantation (2012) 0.81
Regulation of cytochrome P450 2E1 under hypertonic environment through TonEBP in human hepatocytes. Mol Pharmacol (2007) 0.81
Important role of population pharmacokinetic/pharmacodynamic modeling in pediatric therapeutics. J Pediatr (2011) 0.81
No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3. Eur J Clin Pharmacol (2003) 0.80